SHARELeaders Testify before the FDA on Avastin
Yesterday, Helen Schiff testified on behalf of SHARELeaders at the FDA hearings to decide whether Avastin should be approved as a first-line treatment for metastatic breast cancer.
SHARELeaders supported the FDA's decision to revoke approval for use of Avastin to treat metastatic breast cancer. SHARELeaders is a group of graduates of NBCC's Project LEAD, an intensive science program for advocates, who meet monthly at SHARE. SHARE is an organization has not taken a position on this issue. This hearing did NOT address Avastin's use for treatment of other types of cancer.
See media coverage of the hearings, including quotes and a clip from Helen Schiff's testimony. We'll be posting the testimony within the next few days.
Breast Cancer Patients Plead for Avastin Approval
New York Times: Andrew Pollack, Wednesday, June 29, 2011
FDA Debates Safety of Breast Cancer Drug
CNN, Tuesday, June 28, 2011
Avastin Caught in Debate: Emotions Run High for Drug's Use as Breast-Cancer Medicine
Wall Street Journal: Alicia Mundy, Wednesday, June 29, 2011 (You'll need a subscription to access this article. Also note that Helen Schiff is incorrectly identified as a representative of a coalition of breast and ovarian cancer survivors. Helen is representing SHARELeaders, a group of breast cancer advocates.)
Posted June 29, 2011.
« Next Post | » Previous Post